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INTRODUCTION
Over the last few years there has been an increase in the
use of allogeneic peripheral blood stem cell transplantation
(alloPBSCT) to provide hematological rescue after mye-
loablative therapy for the treatment of various advanced
hematological malignancies [1]. Although the first results
are encouraging, the cell content of the infused product and
its effect on engraftment and immunological recovery are
still under discussion [1–4]. Advantages of using PBSCs
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ABSTRACT
To detect the effect of the stem cell source, allogeneic peripheral blood stem cell transplantations (alloPBSCTs)
performed between 1995 and 1997 from human leukocyte antigen (HLA)-identical siblings in 40 patients with acute
and chronic hematological disorders were compared with a historical group of 40 patients with similar variables
who had received allogeneic bone marrow transplants (alloBMTs) between 1993 and 1995. Patients in both groups
were identical except that both the recipient and the donor ages were, on average, higher in the alloPBSCT group
(26 vs. 36 [p 5 0.005] and 27 vs. 32 [p 5 0.024], respectively). Patients received similar therapy excluding posttrans-
plant granulocyte colony-stimulating factor administration (97% in alloBMT vs. 12.5% in alloPBSCT). The median
time to reach neutrophil counts .0.53109/L and platelet counts .203109/L was 13 and 14 days, respectively, in
patients receiving alloPBSCTs compared with 19 and 27 days in patients receiving alloBMTs (p 5 0.0014 and 
p 5 0.0002). The alloPBSCT group required similar transfusions of red blood cells or platelets. The incidence of
grade II–IV acute graft-vs.-host disease (aGVHD) was similar in both groups. However, chronic GVHD (cGVHD)
of all grades developed in 78.1% of patients in the alloPBSCT group after a median follow-up period of 12.5 (range
0.5–34) months. In alloBMT recipients, cGVHD of all grades developed in 21.4% after a median follow-up period
of 38 (range 0.5–62) months (p 5 0.00001). Day 100 transplant-related mortality was also similar: 20% (8 of 40) in
the alloBMT patients and 17.5% (7 of 40) in the alloPBSCT group. Although not statistically significant, a relatively
higher relapse rate occurred in the alloBMT group (21.4 vs. 10.7%). The estimated disease-free survival in month
24 was 51.3% for alloBMT and 54.6% for alloPBSCT, and the estimated overall survival in month 24 was 56.1% for
alloBMT and 64.6% for alloPBSCT. In conclusion, this retrospective comparison suggests that alloPBSCT from
HLA-identical donors is associated with faster engraftment, fewer transfusions, and no greater incidence of
aGVHD, but a high incidence of cGVHD.
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include the relative ease of collection and the rapid hemato-
logical reconstitution compared with those with bone mar-
row (BM). High doses of CD341 cells obtained by PBSC
mobilization improve the speed of hematopoietic recovery
[1–5]. On the other hand, a high number of T lymphocytes
and natural killer (NK) cells in the peripheral blood com-
pared with BM may produce more acute graft-vs.-host dis-
ease (aGVHD) and chronic GVHD (cGVHD) [6]. Some
have reported a high incidence of cGVHD without compar-
ing similar marrow-transplanted patients [7–10]. Similarly,
another group, also without comparing a matched BMT
group, reported a 27% aGVHD (grade II–IV) and 47%
cGVHD after alloPBSCT [11].
In this study, we retrospectively compared 40 patients
receiving human leukocyte antigen (HLA)-identical sibling
PBSCs with a historical group of 40 patients receiving BM
for the treatment of hematological disorders. This study
included chronic myelogenous leukemia (CML) patients in
first chronic phase (within 12 months of diagnosis) and
acute nonlymphoblastic leukemia (ANLL) patients in first
or second complete remission (CR). The end points includ-
ed time to engraftment, transfusion requirements, the inci-
dence of aGVHD and cGVHD, infectious episodes, and the
hematological, cytogenetic, and molecular relapse rate.
PATIENTS AND METHODS
Patient population
Forty patients who underwent alloPBSCT in our depart-
ment between 1995 and 1997 were compared with a similar
historical group of 40 matched allogeneic bone marrow
transplantation (alloBMT) patients studied between 1993
and 1995. There were no statistically significant differences
between the patients in the groups who underwent alloBMT
and alloPBSCT regarding sex mismatch or ABO blood
group mismatch, diagnosis, and the amount of time from
diagnosis to transplantation (Table 1). Recipient ages and
donor ages were higher in the alloPBSCT group than in the
alloBMT group (26 and 27 vs. 36 and 32; p 5 0.005 and
0.024, respectively). The characteristics of the patients are
summarized in Table 1. All patients were given transplants
from their HLA-identical siblings and received the same
conditioning regimen: busulfan, cyclophosphamide, and
GVHD prophylaxis. All patients and donors were similar in
terms of cytomegalovirus (CMV) serology (immunoglobulin
[Ig]G-positive and IgM-negative).
Peripheral stem cell collection from healthy donors
Granulocyte colony-stimulating factor (G-CSF), used to
prime the donors, was given at different doses because of
several ongoing studies on the effect of escalated doses of G-
CSF in healthy donors. Therefore, two patients received 2.5
mg · kg21 · day21 subcutaneously for 10 days, three received 5
mg · kg21 · day21 for 5 days, 30 received 10 mg · kg21 · day21
for 5 days, and five received 15 mg · kg21 · day21 for 5 days.
PBSC collections
In the 10-day schedule of G-CSF, leukapheresis was
started on Day 5 or 6. PBSCs were collected by apheresis
from normal donors using continuous flow blood separation
(Cobe Spectra, COBE BCT, Lakewood, CO; or Fenwall CS
3000, Baxter Healthcare Systems, Deerfield, IL). Donor
venous access was obtained through venipuncture of both
arms. No central venous line insertion was needed. Further
processing was not performed on the collected material.
Median leukapheresis count was 2 (range 1–5). Yields were
transfused the same day they were collected. The first infu-
sion day was accepted as Day 0.
Analyses
PBSC enumeration was done using a procount pro-
genitor cell enumeration system kit (BDIS, San Jose, CA). X-
Y chromosome detection was done in 24-hour cultured lym-
phocytes using denaturation with a DNA probe (Vysis
GmbH, Stuttgart, Germany) as described by the manufac-
turer. To detect chimerism after transplantation, recipients’
blood, epithelial cells found in saliva, and donors’ blood cells
were used as samples. The method of variable nontandem
repeats (VNTR) previously has been described in detail [12].
Prophylaxis and treatment of GVHD
Diagnosis and grading of aGVHD was based on
acceped clinical criteria. Patients were evaluated for
aGVHD if they survived 21 days and had evidence of
engraftment. Cyclosporin A (CsA) and short-term
methotrexate (MTX) were used for GVHD prophylaxis in
all patients. CsA was administered between Day 21 and
180, and was continued if GVHD was detected. MTX was
initiated on Day 1 as a dose of 15 mg/m2 and was given on
Days 3, 6, and 11 as a dose of 10 mg/m2. When clinical
grades III–IV GVHD were established, a high-dose methyl-
prednisolone (10–20 mg · kg21 · day21 i.v. with gradual
tapering) was added. ATG or ALG was added to this treat-
ment if no improvement was observed. Chronic GVHD was
treated with CsA plus methylprednisolone.
Engraftment, relapse, and graft failure
Granulocyte engraftment was defined as the first of 3
consecutive days with a granulocyte count of .0.53109/L.
Platelet engraftment was defined as an unsupported platelet
count of .203109/L on 3 consecutive days. Sex or blood
group mismatches and VNTR polymorphism were used for
detection of engraftment origin and monitorization. Patients
who had hematological evidence of primary disease were
accepted as having hematological relapse. In patients with
CML, Philadelphia positivity starting from 12 months, con-
ventional cytogenetics, and fluorescence in situ hybridization
(FISH) or VNTR were accepted evidence of cytogenetic or
molecular relapse. In cases of acute leukemia, sex and blood
group mismatches and VNTR polymorphism were helpful
in determining relapse. Graft failure was defined as the fail-
ure of neutrophil and platelets in engraftment in the first 28
days after transplantation.
Statistics
Differences between these two groups’ recipient and
donor ages, time to transplantation, mononuclear and
CD341 cell counts, febrile neutropenic days, duration of
antibiotic therapy days, red blood cell (RBC) transfusion, and
platelet transfusion were compared using the Wilcoxon rank-
sum (Mann-Whitney) test. The Chi-square test was used to
compare differences in the two groups for recipient and
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donor sex mismatch, ABO mismatch, diagnosis, transplanta-
tion year, aGVHD grade I–II and grade III–IV, cGVHD lim-
ited and extensive, relapse, transplant-related mortality, and
causes of death. The probabilities of neutrophil and platelet
recovery, disease-free survival (DFS), and overall survival
(OS) were compared using the method of Kaplan-Meier with
log-rank analysis. Cox regression analysis was performed to
detect the hazard ratio for developing cGVHD.
RESULTS
PBSC collections and engraftment
The median number of collected mononuclear cells
(MNCs) and CD341 cells in the PBSC and the BM group
were 5.5 vs. 1.9 3108/kg and 5.4 vs. 3.2 3106/kg (p 5 0.001
and 0.052), respectively (Table 2). Six patients in the alloPB-
SCT group received ,33106/kg CD341 cells, two died due
to sepsis with aplasia. Although 97% of the patients in the
alloBMT group and only 12.5% of the patients in the
alloPBSCT group received G-CSF following transplantation
until engraftment, neutrophil and platelet recovery were
faster in the alloPBSCT group than in the alloBMT group
(13 vs. 19, p 5 0.0014; 14 vs. 27, p 5 0.0002; respectively)
(Table 2, Figs. 1 and 2). A median of 2 units of RBCs and 4
units of platelets, and 1 unit of RBCs and 3 units of platelets
were needed for the alloBMT and the alloPBSCT group,
respectively (p 5 0.15 and p 5 0.10; Table 2). Graft failure
occurred in one patient in each group.
Chimerism studies
Complete chimerism (CC) was documented in the
majority of our patients (Table 3). Sex chromosome–based
FISH and conventional cytogenetics demonstrated CC in
60.0% (20 of 33) of sex-mismatched patients. ABO blood
typing revealed conversion of blood groups to donor type
in 86.1% (31 of 36) of relevant patients. Molecular methods
used to demonstrate chimerism could be applied. VNTR
was uninformative in the four alloBMT sample pairs stud-
ied. However, CC was detected in 80% (12 of 15) of the
patients in the alloPBSCT group.
aGVHD and cGVHD
The occurrence of aGVHD, either grades #II or $II,
was similar in both alloBMT and alloPBSCT groups (Table
2). Five patients died of aGVHD in the alloBMT group, but
none in the alloPBSCT group (Table 4). The incidence of
cGVHD was 78.1% in the alloBPSCT group compared with
21.4% in the alloBMT group (cumulative hazard rate 2.26 6
0.10, p 5 0.0007; Table 2 and Fig. 3). Twenty-one patients
with cGVHD in the alloBPSCT group had hepatic involve-
ment (Table 5), eight of whom were confirmed as having
cGVHD by liver biopsy. One patient with cGVHD of the
liver died of hepatic failure and three died of pulmonary
infection secondary to immunosuppression for GVHD. Two
patients (28.5%) in the alloBMT group and seven patients
(51.8%) in the alloPBSCT group developed aGVHD before
cGVHD. De novo cGVHD occurred after a median of 5
Table 1. Patient characteristics
Group I Group II
(BMT) (PBSCT) p
Number of patients 40 40
Recipient age (years [median]) 26 (16–48) 36 (16–44) 0.005
Donor age (years [median]) 27 (13–47) 32 (16–46) 0.024
Recipient sex (male/female) 25/15 21/19 .0.05
Donor sex (male/female) 21/19 20/20 .0.05
Sex mismatch 12 18 .0.05
ABO blood group mismatch 18 18 .0.05
Diagnosis
AML
CR 1 17 16 —
CR 2 0 3 —
Total 17 19 .0.05
CML (chronic phase) 17 18 .0.05
ALL
CR 1 2 2 —
CR 2 1 0 —
Total 3 2 —
MDS 2 1 —
Adrenoleukodystrophy 1 0 —
Time to TX time (median months) 5.5 (5–16) 7.5 (4–15) .0.05
TX year
1993 6 0 —
1994 23 0 —
1995 11 5 —
1996 0 13 —
1997 0 22 —
ALL, acute lymphoblastic leukemia; AML, acute myeloblastic leukemia; BMT, bone marrow transplantation; CML, chronic myelogenous leukemia; CR, complete
remission; MDS, myelodysplastic syndrome; PBSCT, peripheral blood stem cell transplantation; TX, transplantation.
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months (range 3–11 months) in the alloBMT patients and 6.5
months (range 3.5–11 months) in the alloPBSCT patients.
Chi-square analysis revealed a higher incidence of cGVHD
in patients with prior histories of aGVHD (p 5 0.02).
The CD4/CD8 ratio decreased in alloPBSCT patients
during the follow-up period. The median ratio was 1.6
(range 0.22–1.95) before transplantation and 0.3 (range
0.21–0.52) in the 12th month posttransplant. The median
percentages of CD31 lymphocytes in whole lymphocyte cells
were 23 and 53% in the 1st and 12th months, respectively.
Infections
Febrile neutropenic days numbered 4 (range 0–17 days)
in the alloBMT group and 3 (range 0–18 days, p 5 0.62) in
the alloPBSCT group (Table 2). The duration of antibiotic
therapy was 12 days (range 0–38 days) in alloBMT patients
and 10 days (range 0–30 days) in alloPBSCT patients (p 5
0.27). Veno-occlusive disease occurred in one patient in
each group.
Graft rejection
One patient in the alloPBSCT group underwent trans-
plantation 2 years after the diagnosis of CML. VNTR
analysis revealed recipient cells at the 2nd month and ABO
blood typing showed the patient’s ABO blood group type at
the 4th month.
Outcome and relapse
The overall relapse rate was 21.4% in the alloBMT
group and 10.7% in the alloPBSCT group (p . 0.05;
Table 2). Following alloPBSCT, two patients with acute
myeloblastic leukemia (AML) and one patient with CML
relapsed (Table 2). One of them has received a transplant
at her second CR 6 years after the initial diagnosis. At the
2-month evaluation, despite hematological CR, VNTR
revealed rejection. At the 4-month evaluation, however,
her ABO blood group changed to donor type. At the 8-
month evaluation, marrow blasts were in 40% of BM cells
and VNTR analysis revealed rejection again. She died dur-
ing reinduction chemotherapy. Another patient relapsed
and plasma cell leukemia was confirmed by morphological
immunophenotyping and VNTR analysis, which showed
conversion of CC to mixed chimerism (MC) on peripheral
blood and BM cells. The patient is still alive and in her
second CR 5 months after donor lymphocyte infusion.
Neither patient developed either aGVHD or cGVHD.
The third patient who underwent alloPBSCT for the
treatment of CML relapsed as blastic crisis 12 months
after the procedure while he was suffering from extensive
cGVHD. He did not receive any chemotherapy because of
the cirrhosis that could result from either Hepatitis B virus
infection or cGVHD.
In the early phase posttransplantation, VNTR showed
rejection in two patients with CML. One patient developed
hematological and cytogenetical remission and had the
donor’s blood group 8 months after alloPBSCT. She died
because of cGVHD. VNTR failed to show CC twice for
another patient who had a long time between diagnosis and
transplantation. She was diagnosed as having graft rejection
and died in the 8th month.
Table 2. Results
Group I Group II
(BMT) (PBSCT) p
MNCs 3 108 (median) 1.9 (0.35–28.7) 5.5 (2.5–38.20) 0.001
CD34 3 106 (median) 3.2 (2.15–7.80) 5.4 (0.8–12.4) 0.052
CD31 3 108 (median) — 1.85 (0.45–4.8) —
CD41 3 108 (median) — 1.11 (0.2–2.82) —
CD81 3 108 (median) — 0.96 (0.21–2.27) —
NK cells 3 108 (median) — 0.3 (0.16–1.01) —
Neutrophils .0.53106/L (days [median]) 19 (12–50) 13 (10–32) 0.0014a
PLTs .503106/L (days [median]) 27 (13–70) 14 (11–54) 0.0002a
Febrile neutropenic (days [median]) 4 (0–17) 3 (0–18) 0.27
Duration of antibiotic therapy days (median) 12 (0–38) 10 (0–30) 0.62
RBC transfusion (median) 2 (0–28) 1 (0–12) 0.15
PLT transfusion (median) 4 (1–25) 3 (1–26) 0.10
aGVHD
Grade I–II 15.4% (6/36) 17.1% (6/35) 0.957
Grade III–IV 13.9% (5/36) 14.3% (5/35) 0.961
Total 30.6% (1/36) 31.4% (11/35) 0.936
cGVHD
Limited 17.9% (5/28) 59.3% (19/32) 0.001
Extensive 3.6% (1/28) 18.8% (6/32) 0.067
Total 21.4% (6/28) 78.1% (25/32) 0.00001
Relapse 21.4% (6/28) 10.7% (3/28) 0.275
Disease-free survival (median) 34 (0–62) 12 (0–34) 0.92a
Follow-up month (median) 38 (0.5–62) 12.5 (0.5–34) 0.81a
aLog-rank.
aGVHD, acute graft-vs.-host disease; cGVHD, chronic GVHD; MNCs, mononuclear cells; NK cells, natural killer cells; PLTs, platelets; RBC, red blood cells.
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In the alloBMT group, six patients relapsed after
alloBMT (Table 2): three with AML, one with acute lym-
phoblastic leukemia (ALL), and two with CML. A profile of
relapses in the alloBMT group is as follows: cytogenetic
relapse in two patients with CML 23 and 34 months after
transplantation. Of these, one is still alive 5 months after
donor leukocyte infusion (DLI); the other died of persistent
disease. Hematologic relapse was detected in three patients
with AML 4, 16, and 20 months after transplantation (Table
5). One of these has achieved his second CR after receiving
DLI and two died of persistent diseases. The patients with
ALL died because of the progression of the disease.
In the alloBMT group, a total of 19 patients died of
GVHD (n58), graft failure (n51), interstitial pneumonia
(n52), aplastic death (n54), and relapse (n54; Table 4). The
causes of death in 15 patients in the alloPBSCT group were
GVHD (n55), relapse (n52), aplastic death (n54), graft
failure (n51), graft rejection (n51), interstitial pneumonia
(n51), and hepatic failure (n51, p . 0.05). Transplant-related
mortality at Day 100 was similar for both groups at 20% (8
of 40) vs. 17.5% (7 of 40, p . 0.05). In the alloBMT group,
median DFS and OS were 34 (range 0–62 months) and 38
months (range 0.5–62 months), respectively. In the allo-
PBSCT group, median DFS and OS were 12 (range 0–34
months) and 12.5 months (range 0.5–34 months), respec-
tively (Figs. 4 and 5). The estimated DFS in month 24 was
51.3% for alloBMT and 54.6% for alloPBSCT (p 5 0.81)
and the estimated OS in month 24 was 56.1% for alloBMT
and 64.6% for alloPBSCT (p 5 0.92).
DISCUSSION
Since the first primary allogeneic transplant utilizing
PBSCs collected after G-CSF was reported by Russell et al.
in 1993 [13], various studies have demonstrated the feasibili-
ty of using allogeneic peripheral stem cells collected after
the administration of G-CSF from normal donors
[2–5,11–14].
Table 3. Methods used to demonstrate engrafment origin and relapse
CML AML Other Total
Engraftment origin
Sex mismatch (n533)
Conventional cytogenetics 8 2 — 10
FISH 8 2 — 10
Total 16 4 — 20 (60.0%)
Ph (.6 months, n524);
conventional cytogenetics 19 — — 19 (79.1%)
ABO mismatch (n536);
group typing 17 12 2 31 (86.1%)
HLA polymorphism (n515);
VNTR 4 7 1 12 (80.0%)
Relapse (n59)
Hematological evaluation 1 5 1 7
Conventional cytogenetics 3 ND 0 3
VNTR ND 2 0 2
FISH, fluorescence in situ hybridization; HLA, human leukocyte antigen; VNTR, variable nontandem repeats.
Figure 2. Platelet engraftmentFigure 1. Neutrophil engraftment
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The doses of G-CSF used for the priming of healthy
donors varied during the early days of this treatment modal-
ity. In the literature, there is still no consensus as to the
dosage of G-CSF (2.5–15 mg · kg21 · day21). In the current
study, our donors in the alloPBSCT group received G-CSF
in these ranges and at a median of 10 mg · kg21 · day21.
Platelet and neutrophil engraftments were significantly
faster in the alloPBSCT group than in the alloBMT group,
which is consistent with the data from current literature
[13,15]. The fact that the harvest yields of stem cells were
similar (p 5 0.07), but that the alloPBSCT group retained
more MNCs (p 5 0.04) than the alloBMT group might be a
reason for the faster engraftment. It has been suggested that
CD341 cell count must be at least 2.53106/kg for successful
engraftment [15]. Among all patients in the allo-
PBSCT group, one patient who received ,23106/kg
CD341 cells died on the12th day from sepsis with aplasia.
Rapid engraftment in alloPBSCT patients resulted in fewer
days on antibiotics and fewer days of fever. There were, oth-
erwise, no statistical differences.
Consistent with our data, Pavletic et al. showed that the
number of patients who spent days on antibiotics was not
statistically greater in the alloBMT group than in the
alloPBSCT group [16]. Pavletic et al. also demonstrated that
the median transfusion of platelets and erythrocytes was
higher in patients who were given transplants of alloBMT,
but only platelet need was statistically less [16]. Bensinger et
al. reported that the need for transfusions of RBCs and
platelets was significantly higher in patients undergoing
alloBMT in comparison to patients undergoing alloPBSCT
[14]. In our study, the median units of platelet and erythro-
cyte transfusions were higher in the alloBMT group, but
these differences were not statistically significant. There
were no differences between the two groups regarding graft
failure and transplant-related deaths.
In this study, the incidence of aGVHD was similar in
both groups, but the incidence of cGVHD was higher in
patients undergoing alloPBSCT than in those undergoing
alloBMT, as in the preliminary study results from previous
work [17,18]. Most cases of cGVHD were de novo and
appeared after CsA was tapered off, starting from the 6th
month. Potential predictors of cGVHD, including donor
age and pretransplant donor and recipient CMV serostatus,
were similar in both groups, whereas patient age was higher
in the alloPBSCT group (a factor associated with an
increased risk of developing cGVHD) [19–21]. In addition,
the higher incidence of cGVHD in patients receiving an
alloPBSCT may also be related to the content of the infused
MNCs and lymphocytes. As previously reported, the exis-
tence of prior aGVHD is another risk factor. In both
groups, cGVHD developed more often in patients who had
previously had aGVHD [21].
Initial studies reported an acceptable rate of cGVHD in
patients receiving alloPBSCT compared with a historical
group of alloBMT patients. Some groups with a longer follow-
up period reported an increased incidence of cGVHD in
patients undergoing alloPBSCT [22,23]. Storek et al. report-
ed an increased incidence of cGVHD as the duration of fol-
low-up time increased in patients with hematological malig-
nancies undergoing alloPBSCT [22]. In that study, cGVHD
developed at a median of 4 months (range) after transplanta-
tion. Storek et al. speculated that increased incidence of
cGVHD in alloPBSCT patients may be related to an
unmodified blood stem cell graft, which contains 2 logs more
of T lymphocytes than an unmodified marrow graft [22]. In
addition, Talmadge et al. reported that alloPBSCT patients
had a significantly faster recovery of NK cells, CD41 T cells,
Table 5. Organ involvement in cGVHD
BMT (n56) PBSCT (n525)
Liver 5 (83.3%) 21 (84.0 %)
Skin 5 (83.3%) 12 (48.0 %)
Eyes 1 (16.6%) 3 (12.0%)
Gastrointestinal tract 3 (50.0%) 6 (24.0%)
Hematopoietic 2 (33.3%) 7 (28.0%)
Pulmonary 1 (16.6%) 7 (24.0%)
Figure 3. Cumulative hazard rate of cGVHD
Table 4. Survival characteristics
Group I Group II
(BMT) (PBSCT) p
Alive 20/40 25/40 —
Dead 19/40 15/40 —
Loss of follow-up 1/40 — —
Transplant-related mortality
(first 100 days) 20% (8/40) 17.5% (7/40) .0.05
Causes of death
GVHD (total) 8 5 .0.05
Acute 5 0 —
Chronic 3 5 —
Relapse 4 2 .0.05
Early death 4 4 .0.05
Graft failure 1 1 .0.05
Graft rejection 0 1 .0.05
Interstitial pneumonia 2 1 .0.05
Hepatic failure 0 1 .0.05
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and T-cell receptor γδ [24]. As in the Talmadge et al. study,
we found a gradual decrease of the CD4/CD8 cell ratio in
the alloPBSCT group and an increase in the CD31 cell
counts. Reactions to minor histocompatibility antigens,
which play an important role in the development of
cGVHD, is mediated largely, though not exclusively, by
CD81 cells [25,26]. After transplantation, the decrease of the
CD4/CD8 cell ratio and the increase in CD31 cell counts
may be responsible for cGVHD.
It has been demonstrated that GVHD is associated with
an antileukemic effect, hence the lower incidence of relapse
in patients who developed GVHD than in those who did
not [27–29]. Some in vivo human studies showed less relapse
in alloPBSCT [30]. In our study, the relapse rate was not
statistically different between the two groups. Of the nine
patients in the study who relapsed, one in both groups
developed cGVHD before relapse. In addition, in the
alloPBSCT group, one patient who relapsed had conditions
that might explain this event: ,33106/kg of CD341 cells, a
longer time to transplantation, and, most significantly,
transplantation at her second CR. DFS was significantly
higher in alloBMT due to the prominent differences
between follow-up periods in both groups.
In contrast to some current studies in which the liver is
usually not the first organ involved in cGVHD, in the
alloPBSCT group, the liver was the most affected organ
from cGVHD in our study [22,23]. Despite the fact that the
patients with liver cGVHD received megadoses of pred-
nisolone, they did not respond to treatment and three
patients died. Of these, two died due to cGVHD secondary
to immunosuppression and pulmonary infection and failure;
the third death was due to hepatic failure.
Using several methods, it is possible to evaluate
chimerism following transplantation. For this purpose, ABO
blood group antigen typing, sex chromosome analysis with
FISH by using sex probes, and conventional cytogenetics
have been used. Recently, polymerase chain reaction (PCR)-
based VNTR, the most sensitive, rapid, and powerful tech-
nique, has been applied in this field [12]. We were able to
use this technique for almost all alloPBSCT patients, and all
but three demonstrated CC. Most of the patients in both
groups had donor type karyotype and blood group, which
shows the success of transplantation. On the other hand,
MC may represent minimal residual disease and predict
hematological relapse as has been previously reported. At
the time hematological relapse occurred, sequential VNTR
analysis showed a conversion from CC to MC in two
patients with AML. Another patient’s VNTR analysis
demonstrated rejection at the time she was in hematological
CR and had the donor’s blood group. She relapsed 5 months
after the VNTR analysis. Of two patients with CML whose
early phase VNTR analysis showed rejection, one achieved
hematologic and cytogenetic remission and the donor’s
blood group, but the other never did. These findings sup-
port the idea that the presence of residual malignant cells of
the recipient can only be detected by VNTR, which is a
very sensitive molecular method. However, the results of
VNTR do not clearly demonstrate forthcoming relapse in
patients with CML in the early postengraftment phase.
In our study, we report the follow-up findings of allo-
PBSCT patients and their leukemic behavior based on various
methods that have been extensively analyzed and published.
ACKNOWLEDGMENTS
The authors thank Alev Türker and Asuman
Sunguroğlu, for their efforts in cytogenetic studies. We also
thank Penelope Cumler for manuscript revision and Atilla
Halil Elhan for statistical analysis.
REFERENCES
1 Invards D, Kessinger A: Peripheral blood stem cell transplantation:
historical perspective, current status, and prospect for the future.
Transfus Med Rev 6:183, 1992.
2 Schmitz N, Dreger P, Suttorp M, Rohwedder EB, Haferlach T, Löffler
H, Hunter A, Russell NH: Primary transplantation of allogeneic periph-
eral blood progenitor cells mobilized by Filgrastim (G-CSF). Blood
85:1666, 1995.
3 Korbling M, Przepiorka D, Huh YO, Engel H, Besien K, Giralt S,
Figure 5. Disease-free survival at 24 monthsFigure 4. Overall survival analysis of patients
Comparison of AlloPBSCT and AlloBMT
35B B & M T
Andersson B, Kleine HD, Seong D, Deisseroth AB, Andreeff M, Champlin R:
Allogeneic blood stem cell transplantation for refractory leukemia and
lymphoma: potential advantage of blood over marrow allografts. Blood
85:1659, 1995.
4 Bensinger WI, Clift RA, Anasetti C, Applebaum FA, Demirer T, Row-
ley S, Sandmaier BM, Torok-Storb B, Storb R, Buckner D: Transplantation
of allogeneic peripheral stem cells mobilized by recombinant human
granulocyte colony stimulating factor. Stem Cells 14:90, 1996.
5 Dreger P, Haferlach T, Eckstein V, Jacobs S, Suttorp M, Loffler H,
Muller-Ruchholtz W, Schmitz N: G-CSF mobilized peripheral blood
progenitor cells for allogeneic transplantation: safety, kinetics of mobi-
lization and composition of the graft. Br J Haematol 87:609, 1994.
6 Ferrara JLM, Deeg HJ, Burakof SJ: Graft-vs.-Host Disease, 2nd edi-
tion. New York, NY: Marcel Dekker, 1997.
7 Majolino I, Saglio G, Scime R, Serra A, Cavallaro AM, Fiandaca T,
Vasta S, Pampinella M, Catania P, Indoniva A, Marceno R, Santora A:
High incidence of chronic GVHD after primary allogeneic peripheral
blood stem cell transplantation in patients with hematologic malignan-
cies. Bone Marrow Transplant 17:555, 1996.
8 Urbano-Ispizua A, Garcia-Conde J, Brunet S, Hernandez F, Sanz G,
Alegre A, Petit J, Bargay J, Vivancos P, Solano C, Ojeda E, Domingo A,
Rozman C, for the Spanish Group of alloPBPCT: High incidence of chron-
ic graft versus host disease (GVHD) after allogeneic peripheral blood
progenitor cell transplantation (allo-PBPCT) from matched related
donors. Blood 88 (Suppl 1):2455a, 1996.
9 Körbling M, Mirza M, Thall P, Przepiorka D, Anderlini P, Huh Y,
Fischer H, Fahmy H, Champlin R: 100 HLA-identical allogeneic blood
stem cell transplantations: the MD Anderson Cancer Center experi-
ence. Bone Marrow Transplant 19 (Suppl 1):S72, 1997.
10 Russell JA, Desai S, Herbur B, Brown C, Luider J, Ruether JD, Stew-
art D, Chaudhry A, Booth K, Jorgeson K, Coppes MJ, Turner AR, Larratt
L, Poon MC, Klassen J: Partially mismatched blood cell transplantation
for high-risk hematologic malignancy. Bone Marrow Transplant
19:861, 1997.
11 Miflin G, Russell NH, Hutchinson RM, Morgan G, Potter M, Pagliuca
A, Marsh J, Bell A, Milligan D, Lumley M, Cook G, Franklin I: Allogeneic
peripheral blood stem cell transplantation for haematological malignan-
cies—an analysis of kinetics of engraftment and GVHD risk. Bone
Marrow Transplant 19:9, 1997.
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